Podcasts about pharmd

Retirement isn't just about the numbers. Tim Ulbrich, PharmD and Tim Baker, CFP® and Registered Life Planner, explore how life planning can help you design a retirement filled with purpose, meaning, and fulfillment, not just financial security. Episode Summary When it comes to preparing for retirement, most conversations focus on the financial side—things like income planning, Social Security timing, withdrawal strategies, and tax-efficient investing. But true retirement readiness goes beyond the numbers. In this episode, Tim Ulbrich, PharmD, is joined by Tim Baker, CFP® and Registered Life Planner, to explore how life planning can help you design a retirement that's rich with meaning, purpose, and fulfillment, not just financial security. As you step away from decades of work—often after raising kids, building a career, and living within a structured routine—you enter a new phase of life where the biggest challenges aren't just financial, they're personal. Who are you now? What does your ideal day look like? How do you make this season of life one that aligns with your values and brings you joy? In this episode, you'll learn: What life planning is and how it complements financial planning How to navigate the personal and emotional transition into retirement Practical ways to align your money with your values and goals How to create a vision for a fulfilling and purpose-driven retirement Whether you're approaching retirement or simply thinking ahead, this conversation will help you see how life planning can make the next chapter not only financially sound but deeply satisfying. Mentioned on the Show Your Financial Pharmacist Your Financial Pharmacist on YouTube YFP 394: Crafting a Rich Life in Retirement: Insights from David Zgarrick, PhD Vanguard Study Advisor's Alpha Changes in US Family Finances from 2019 to 2022: The Federal Reserve Board of Governors

About this episode: Pharmacies do a lot more than dispense medications. In this episode: Christina Madison, known online as the Public Health Pharmacist, explains how pharmacists and pharmacies are able to support critical health needs in communities across the country. Guest: Christina Madison, PharmD, FCCP, is a clinical pharmacist and the founder and CEO of The Public Health Pharmacist, PLLC. Host: Dr. Josh Sharfstein is distinguished professor of the practice in Health Policy and Management, a pediatrician, and former secretary of Maryland's Health Department. Show links and related content: The Public Health Pharmacist—http://thepublichealthpharmacist.com The Public Health Pharmacist—Instagram Transcript information: Looking for episode transcripts? Open our podcast on the Apple Podcasts app (desktop or mobile) or the Spotify mobile app to access an auto-generated transcript of any episode. Closed captioning is also available for every episode on our YouTube channel. Contact us: Have a question about something you heard? Looking for a transcript? Want to suggest a topic or guest? Contact us via email or visit our website. Follow us: @‌PublicHealthPod on Bluesky @‌JohnsHopkinsSPH on Instagram @‌JohnsHopkinsSPH on Facebook @‌PublicHealthOnCall on YouTube Here's our RSS feed Note: These podcasts are a conversation between the participants, and do not represent the position of Johns Hopkins University.

Today's guest, Scleroderma Warrior Dr. Joseph Washington, is the definition of resilience and perseverance. His journey began with Raynaud's symptoms in junior high, but it wasn't until pharmacy school that he was diagnosed with diffuse systemic sclerosis. So much has happened in just four years since then, and I can't wait for you to hear his inspiring story. 

On this episode, we review irritable bowel syndrome (IBS) and describe its clinical presentations, subtypes, and pathophysiology. We discuss current guidelines and evidence-based treatment strategies for managing IBS, including pharmacological, dietary, and lifestyle interventions. We also compare and contrast the efficacy, safety profiles, and appropriate use of IBS therapies, including medications, dietary modifications, and symptom-specific management strategies. Cole and I are happy to share that our listeners can claim ACPE-accredited continuing education for listening to this podcast episode! We have continued to partner with freeCE.com to provide listeners with the opportunity to claim 1-hour of continuing education credit for select episodes. For existing Unlimited (Gold) freeCE members, this CE option is included in your membership benefits at no additional cost! A password, which will be given at some point during this episode, is required to access the post-activity test. To earn credit for this episode, visit the following link below to go to freeCE's website: https://www.freece.com/ If you're not currently a freeCE member, we definitely suggest you explore all the benefits of their Unlimited Membership on their website and earn CE for listening to this podcast. Thanks for listening! If you want to support the podcast, check out our Patreon account. Subscribers will have access to all previous and new pharmacotherapy lectures as well as downloadable PowerPoint slides for each lecture. If you purchase an annual membership, you'll also get a free digital copy of High-Powered Medicine 3rd edition by Dr. Alex Poppen, PharmD. HPM is a book/website database of summaries for over 150 landmark clinical trials.You can visit our Patreon page at the website below:  www.patreon.com/corconsultrx We want to give a big thanks to Dr. Alex Poppen, PharmD and High-Powered Medicine for sponsoring the podcast..  You can get a copy of HPM at the links below:  Purchase a subscription or PDF copy - https://highpoweredmedicine.com/ Purchase the paperback and hardcover - Barnes and Noble website We want to say thank you to our sponsor, Pyrls. Try out their drug information app today. Visit the website below for a free trial: www.pyrls.com/corconsultrx We also want to thank our sponsor Freed AI. Freed is an AI scribe that listens, prepares your SOAP notes, and writes patient instructions. Charting is done before your patient walks out of the room. You can try 10 notes for free and after that it only costs $99/month. Visit the website below for more information: https://www.getfreed.ai/  If you have any questions for Cole or me, reach out to us via e-mail: Mike - mcorvino@corconsultrx.com Cole - cswanson@corconsultrx.com

Send us a textBuckle up, babes! Janey's going to tell us about the most insane assassination you may have never heard of! Let us know if you followed this story when it happened, because Janey's never stopped thinking about it. Sources:“Kim Jong-nam Says N. Korean Regime Won't Last Long”, by The Chosun Daily in 2012. “Kim Jong-il's son reappears in Singapore one year after feeling Macau” from The Shanghaiist.   “Was Kim Jong Nam in Sights of His Paranoid Half-Brother?” by Yoshihiro Makino for Asahi Shimbun. Murder at the Airport: The Brazen Attack on Kim Jong-Nam, by Reuters “Assassins review— unravelling the bizarre death of Kim Jong-nam” by Adam Sweeting for The Arts Desk. “How North Korea got away with the assassination of Kim Jong-nam” by Hannah Ellis-Peterson and Benjamin Haas for The Guardian. Dr. Harini Bhat, PharmD (@tilscience) explaining VX2 Support the showCheck out our books (and support local bookstores!) on our Bookshop.org affiliate account!Starting your own podcast with your very cool best friend? Try hosting on Buzzsprout (and get a $20 Amazon gift card!)Want more??Visit our website!Join our Patreon!Shop the merch at TeePublic!If you liked these stories, let us know on our various socials!InstagramTiktokGoodreadsAnd email us at sortofthestory@gmail.com

“I think that this is an area that is exploding. Working with drug development, I see new agents all the time, with unique targets I've never heard about, with targets I have heard about used in a different way. So, I really think we're going to see more and more bispecifics. A lot of these drugs are used second line, third line, fourth line. I would not be surprised if they moved up in treatment, especially as we learn safer ways to give these drugs,” ONS member Moe Schwartz, PharmD, BCOP, FHOP, professor of pharmacy practice at the James L. Winkle College of Pharmacy at the University of Cincinnati, OH, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about bispecific antibodies.  Music Credit: “Fireflies and Stardust” by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Earn 0.5 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by October 3, 2026. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learner will report an increase in knowledge related to the use of bispecific antibodies in the treatment of cancer. Episode Notes  Complete this evaluation for free NCPD. ONS Podcast™ episodes: Pharmacology 101 series Episode 275: Bispecific Monoclonal Antibodies in Hematologic Cancers and Solid Tumors Episode 261: CAR T-Cell Therapy for Hematologic Malignancies Requires Education and Navigation Episode 176: Oncologic Emergencies: Cytokine Release Syndrome ONS Voice articles: An Oncology Nurse's Guide to Bispecific Antibodies Bispecific Antibodies Cross-Discipline Cancer Care ONS Voice oncology drug reference sheets: Amivantamab-Vmjw Blinatumomab Epcoritamab-Bysp Glofitamab-Gxbm Mosunetuzumab-Axgb Tebentafusp-Tebn Teclistamab-Cqyv ONS book: Guide to Cancer Immunotherapy (second edition) ONS course: ONS/ONCC® Chemotherapy Immunotherapy Certificate™ Clinical Journal of Oncology Nursing article: Optimizing Transitions of Care in Multiple Myeloma Immunotherapy: Nurse Roles Other ONS resources: Bispecific Antibodies Video Bispecifics Huddle Card Cytokine Release Syndrome Huddle Card Immune Effector Cell–Associated Neurotoxicity Syndrome Huddle Card DailyMed homepage Hematology/Oncology Pharmacy Association late-breaking news article: The Emerging Use of Bispecific Antibodies with Chemotherapy in Diffuse Large B-Cell Lymphoma To discuss the information in this episode with other oncology nurses, visit the ONS communities.  To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org Highlights From This Episode “It was 2014 that most of us think of as the beginning of bispecifics in cancer, and that was with approval of blinatumomab. That was granted accelerated approval for the treatment of patients with Philadelphia chromosome–negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia. It is a bispecific that targets CD19-expressing tumor cells and CD3 on T cells. It's the original bispecific T-cell engager and is often called a ‘BiTE.'” TS 2:11 “The term ‘bispecific' means that this is an artificial protein that's developed to hit two different antigens simultaneously. They can be two different epitopes on the same antigen. They can be an antigen on a cancer cell and CD3 on a T cell that kind of recruits the T cell to the cancer. So, there are different types [of bispecific antibodies]. The subtype that we often talk about are bispecific T-cell engagers, which are those bispecifics that do target the T cell. And currently, the target on the T cell that's utilized is the CD3 molecule. That's not the only one that will be used in the future because there's a lot of work being done on other types of T-cell engagers.” TS 4:21 “The targets for lymphoma are CD20. Those are bispecific T-cell engagers that hit CD20 on the lymphoma cell, as well as CD3 on a T cell. ... In myeloma, we have two different targets that have been utilized. One is BCMA or B-cell maturation antigen. That sits on the surface of myeloma cells and on some healthy B cells. ... There's also a target used in myeloma that's called GPRC5D, which stands for G protein–coupled receptor, class C, group 5, member D. ... In small cell lung cancer, there's delta-like ligand 3 (DLL3); it's part of the NOTCH pathway. ... And then this year, we've had a couple agents come out that target HER2.” TS 6:52 “[Toxicities] are very dependent on what your target is. ... The bispecific T-cell engager that's used in myeloma that targets the GPRC5D is also expressed on tissues that produce hard keratin like hair follicles and actually, within the tongue. So the toxicities that we see with that agent are something you wouldn't expect to see if you were using a myeloma agent. You see nail and skin issues. You see taste problems. So it's very specific about the target, which says to me, that every time a new one of these agents comes out, I have to learn about the target that helps me learn about the toxicity. I find that fascinating and really appreciate that.” TS 16:19 “Cytokine release syndrome has been one of the areas that drug development has really focused on to see how they can help mitigate the severity [of it]. ... [One of] the strategies that has been incorporated and studied in clinical trials is the step-up dosing scheme. [It's] where you give initial small doses and over time, increase the dose to the dose you're going to continue with. Usually, monitoring in the hospital is required by the FDA approval for anywhere from 28–48 hours for the first couple of doses. And that's a real common strategy that you'll see. Premedication with H2 blockers, H1 blockers, sometimes steroids. These are also things that are incorporated within the approvals of these drugs and are important to look at.” TS 20:53

GLP-1 therapies are transforming pharmacy benefits, and Express Scripts is leading the way. Harold Carter, PharmD, SVP of Trade Relations, joins host Eric Glazer to discuss how one of the nation's largest PBMs is navigating this disruptive moment in healthcare. Harold shares how Express Scripts is: Capping costs of GLP-1 therapies to expand patient access while keeping plan spending predictable. Redesigning funding models to strike a balance between affordability, predictability, and outcomes. Leveraging digital tools and AI to reduce friction in the member experience and support long-term adherence. Rethinking formularies not just as cost-control tools but as part of a broader population health and behavioral change ecosystem. You'll also hear his forward-looking perspective on how PBMs will evolve over the next three to five years, and the key questions health plans and employers should be asking today to prepare for the future of pharmacy benefits. About Dr. Harold Carter:   Harold Carter, PharmD, is responsible for leading all interactions and contracting with pharmaceutical manufacturers and oversees strategy and management of Express Scripts' drug formularies, data & insights, client underwriting, and product strategy and development. In his nearly 14 years with the organization, Harold has held numerous leadership roles oriented around critical efforts to lower the cost of prescription drugs and ensuring medication access for Express Scripts clients and members. Harold's previous responsibilities include oversight of the organization's medical pharma contracting and drug procurement teams, as well as leading the strategy, development and execution of Express Scripts' wholesale market, value-based solutions and generic strategy, and development of Express Scripts' advanced utilization management solutions.  In addition to his work at Express Scripts, Harold serves on numerous boards including LifeWise Stl Board of Directors, St. Louis University High School Board of Trustees and IVI Board of Directors. Harold earned his doctorate in pharmacy from St. Louis College of Pharmacy.   Partner with Bright Spots Ventures: If you are interested in speaking with the Bright Spots Ventures team to brainstorm how we can help you grow your business via content and relationships, email hkrish@brightspotsventures.com  About Bright Spots Ventures: Bright Spots Ventures is a healthcare strategy and engagement company that creates content, communities, and connections to accelerate innovation. We help healthcare leaders discover what's working, and how to scale it. By bringing together health plan, hospital, and solution leaders, we facilitate the exchange of ideas that lead to measurable impact. Through our podcast, executive councils, private events, and go-to-market strategy work, we surface and amplify the “bright spots” in healthcare, proven innovations others can learn from and replicate. At our core, we exist to create trusted relationships that make real progress possible. Visit our website at www.brightspotsinhealthcare.com.

Is it possible for a pharmacist to save $1M by 40? In this episode, we break down the math, explore money mindsets, and share my journey from –$225K in debt after residency to reaching millionaire status with practical strategies to build wealth. Episode Summary In this episode, we tackle one of the most common (and debated) money questions: Is it realistic for a pharmacist to reach $1 million by age 40? YFP Co-Founder & CEO, Tim Ulbrich, PharmD breaks down the math, explores the mindset shifts that matter most, and shares some of his own story of going from –$225,000 in net worth after residency to crossing the seven-figure mark. You'll learn: ✅ How to calculate what it actually takes to hit $1M ✅ Why your money beliefs may help or hold you back ✅ Strategies like automating savings, tracking net worth & boosting financial IQ ✅ The importance of “playing financial defense” with debt and expenses This episode isn't just about hitting a number, it's about what that milestone means for your financial independence, freedom, and peace of mind. Mentioned on the Show YFP Compound Interest Calculator The Millionaire Next Door by Dr. Tom Stanley Watch the Your Financial Pharmacist Podcast on YouTube Learn More About Your Financial Pharmacist

Transform your approach to CLL care with insights from clinical pharmacy expert, "Kelsey Marciano, PharmD, BCOP,UCHealth. This podcast unpacks the latest strategies for treatment selection and toxicity management—empowering oncology pharmacists to lead confidently, maximize patient outcomes, and deliver next-level care in the evolving era of oral targeted therapies.

In this episode, Tamara sits down with Carrie Krebs, PharmD, to talk about the important role pharmacists play in hospice care. Together, they cover commonly used medications, key regulations, deciding when to stop certain drugs, and more. Carrie also opens up with a personal story about her own loved one's hospice journey.

In this episode of The Birth Lounge Podcast, HeHe sits down with clinical pharmacist Dr. Michaela Wachal to unpack the controversy surrounding Tylenol (acetaminophen) use in pregnancy and its potential links to autism and other neurodevelopmental concerns. Together, they dive into what the research actually says (and doesn't say), why transparency and informed consent are so important, and how to navigate decisions around medications in pregnancy with confidence. Dr. Wachal also highlights the bigger picture, like how genetics, environmental toxins, and even maternal stress can play a role in outcomes, and why caring for yourself is just as critical as any prescription. This conversation is packed with nuance, evidence, and practical takeaways to help you feel informed, empowered, and ready to advocate for yourself as you make decisions about your pregnancy care. 00:00 Introduction and Media Misrepresentation 01:05 Personal Story and Birth Lounge App 02:16 Empowering Prenatal Conversations 05:26 Emergency Use Authorization Episode 07:34 Interview with Dr. Michaela Wachal 09:14 Medication Safety in Pregnancy 12:37 Pharmaceutical Industry Failures 15:20 Personal Journey and Advocacy 18:55 Questioning Medical Norms 21:15 Tylenol and Toxins 23:34 Aluminum in Vaccines 27:32 The Importance of Transparency 37:05 Advocating for Education and Understanding 37:51 The Power of Asking Questions 40:21 Nesting and Preparing for Baby 43:17 Managing Fevers During Pregnancy 52:01 Environmental Toxins and Health 01:00:41 Therapies and Support for Children on the Spectrum 01:09:27 Final Thoughts and Encouragement   Guest Bio: Michaela Wachal, PharmD, CSP, is a clinical pharmacist, Certified Specialty Pharmacist, and Clinical Accreditation Manager with nearly a decade of experience in specialty pharmacy. She holds a Doctor of Pharmacy degree from the University of Nebraska Medical Center and a Bachelor of Science in Biochemistry from Doane University. Throughout her career, she's specialized in complex conditions including oncology, fertility, endocrinology, immunology, mental health, and inflammatory diseases—always with a passion for improving patient care, optimizing healthcare systems, and empowering women in medicine. Michaela is also a mom of three, including one child with autism, ADHD, and anxiety, which ignited her deep interest in neurodiversity, integrative health, and individualized medicine. After navigating her own family's challenges, she began researching functional and evidence-based approaches to support children and families living with complex needs. Online, Michaela shares insights from scientific studies on autism, ADHD, vaccines, autoimmune conditions, toxins, and more, always with a focus on helping parents make informed, evidence-based choices. Her work blends professional expertise with personal passion, making her a trusted voice in both the pharmacy world and the parenting community.   INSTAGRAM: Connect with HeHe on IG  Connect with Dr. Wachal on IG    BIRTH EDUCATION: Join The Birth Lounge here for judgment-free childbirth education that prepares you for an informed birth and how to confidently navigate hospital policy to have a trauma-free labor experience!   Download The Birth Lounge App for birth & postpartum prep delivered straight to your phone!   RESEARCH MENTIONED: 2021 there's a call for action published supported by 91 scientists, clinicians and public health professionals across the globe recommended that pregnant women should be cautioned at the beginning of pregnancy to forego APAP unless it is medically indicated and to minimize the exposure by using the lowest effective dose for shortest possible time https://pubmed.ncbi.nlm.nih.gov/34556849/   Boston Birth cohort published in 2020 looked at acetaminophen metabolites in cord blood samples collected at birth and unchanged acetaminophen levels were detected in all cord plasma samples and acetaminophen burden was associated with higher odds of ADHD  and ASD daignosis there was a 2.3 to 3.5 increased risk for ADHD and 1.6 to 4.1 increased risk for ASD https://pubmed.ncbi.nlm.nih.gov/31664451/   Recently in August Harvard did an analysis using the Navigation Guide methodology that supports evidence consistent with an association between acetaminophen exposure during pregnancy and increased incidence of Neurodevelopmental disorders. This included 46 studies with 27 reporting positive associations with the higher quality studies more likely to show positive correlations https://ehjournal.biomedcentral.com/articles/10.1186/s12940-025-01208-0   Nurses Health Study https://pubmed.ncbi.nlm.nih.gov/30923825/ Spanish birth cohort where acetaminophen exposure was associated with more hyperactivity/impulsivity https://pubmed.ncbi.nlm.nih.gov/27353198/   In 2018 there was a review that showed that 9 prospective cohort studies that all suggested an association between prenatal APAP exposure and neurodevelopmental outcomes - ADHD, ASD or lower IQ and longer duration was associated with increased risk https://pubmed.ncbi.nlm.nih.gov/29341895/   2022 a prospective cohort study in Pennsylvania looked at 2,423 moms using data and children who were exposed to APAP during pregnancy scored higher for child behaviors, sleep problems and attention problems  https://pubmed.ncbi.nlm.nih.gov/36170224/ Keywords: Tylenol pregnancy, acetaminophen pregnancy, Tylenol autism risk, pregnancy medication safety, prenatal care, evidence-based pregnancy, maternal health, neurodevelopment, pregnancy decision making, informed consent pregnancy, pregnancy medications, Dr. Michaela Wachal, Birth Lounge podcast, pregnancy self-care, pregnancy toxins

Ketogenic therapy for mental illness is gaining attention, with more and more patients looking to incorporate this strategy into their care plan.The problem is that sometimes patients struggle to find providers to help them and providers often lack the expertise and confidence to prescribe this strategy.These issues led to a light bulb moment for Dr. Kelly, “We've got to capacity build, we have to figure this out.”In this interview, Dr. Bret Scher speaks with Deanna Kelly, PharmD, internationally recognized for her work in schizophrenia, psychiatric pharmacology, and metabolic health, who is now pioneering an innovative project of her own called Live it, Launch it.This first-of-its-kind study is Dr. Kelly's brainchild, designed to train clinicians through direct experience in an effort to increase clinical expertise in metabolic and ketogenic therapies. Participants don't just learn the science, they actually live a ketogenic diet themselves, gaining confidence, competence, and practical insight to better guide patients struggling with psychiatric disorders.In this interview, you'll discover:Why so many families are searching for trained ketogenic therapy cliniciansWhy personal experience may be the missing link in clinical adoptionThe potential widespread clinical impact of Live it, Launch it.The potential of ketogenic therapy alongside medications like GLP-1sAn update on Dr. Kelly's in-patient ketogenic therapy for schizophrenia studyBy training clinicians to live it before they launch it, this study could change how psychiatric care is delivered, and help meet the growing demand for clinical guidance in ketogenic therapy.Expert Featured:Dr. Deanna KellyDirector of the Maryland Psychiatric Research CenterX: https://x.com/profdeannakResources Mentioned:Why Did the Maryland Health Department Halt a Critical Schizophrenia Study?https://youtu.be/tzPlQ6dJwe8Stanford Study Shows Promise of Ketohttps://www.metabolicmind.org/trials/featured/stanford-study-shows-promise-of-keto/Free CME Clinician Trainings:Are you a clinician who would like to learn more about the science behind these therapies and how to implement them in practice? Earn CME with our growing library of courses from some of the top experts in the field including Dr. Chris Palmer, Dr. Georgia Ede, Dr. Matthew Bernstein and Dr. Bret Scher with more coming soon.Our courses have been made FREE by grants from Baszucki Group, so we can spread these powerful therapies as widely as possible. Earn CME/CNE credits:https://www.metabolicmind.org/for-clinicians/trainings-courses/?utm_medium=organic-social&utm_source=youtube&utm_campaign=cme-ytFollow our channel for more information and education from Bret Scher, MD, FACC, including interviews with leading experts in Metabolic Psychiatry.Learn more about metabolic psychiatry and find helpful resources at https://metabolicmind.org/About us:Metabolic Mind is a non-profit initiative of...

This podcast explores unique opportunities for pharmacists to pursue a Fulbright Scholar Award, highlighting pathways for academic exchange, research, and global health collaboration. Featuring insights from a recent Fulbright recipient, the discussion covers how pharmacists can contribute to and benefit from international scholarship and cultural diplomacy.  The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.

Discover the essential contributions of pharmacists in patient care with We're Your Pharmacist, a monthly podcast from ASHP. This episode features Charrai Byrd, director of pharmacy services at New York-Presbyterian Hospital, as he shares what drew him to a career in pharmacy. Gain insights into the diverse opportunities within the pharmacy profession and learn how pharmacists are making a difference every day.  The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.

On "This Week in Pharmacy" for September 26th, we're talking about Trust in Healthcare, World Pharmacists Day, and Cell & Gene Therapy. Today's co-host is Dr. Melissa Smith, PharmD CPH with Florida PGx Consulting LLC. https://www.floridapgxconsulting.com/  First, #TWIRx News - the FDA approves Inluriyo imlunestrant on 9/25/2025 which is to treat estrogen receptor-positive, human epidermal growth factor receptor 2-negative, estrogen receptor-1-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy. (https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2025)  Second, Nested-Knowledge - is going to revolutionize information access and leverage. This is a powerful tool with evidence synthesis tools for medical researchers. This will help accelerate, collaborate, automate and share the latest and personalized treatment plans. (https://nested-knowledge.com/) Next, announcing "Evidence based Podcasting", the new standard in audio learning for Providers and next level in podcast Continuing Medical Education (CME). (https://pharmacypodcast.com/2025/09/26/evidence-based-podcasting-and-the-future-of-medical-education/ ) Shout out to Nick Calla with Orsini, a leader in rare disease pharmacy solutions, has been chosen by Crinetics Pharmaceuticals, Inc., as a specialty pharmacy partner for PALSONIFY™ (paltusotine), a nonpeptide, selectively-targeted somatostatin receptor type 2 nonpeptide (SST2) agonist. (https://www.wvnews.com/news/around_the_web/partners/pr_newswire/subject/licensing_marketing_agreements/orsini-selected-as-specialty-pharmacy-partner-for-crinetics-palsonify-paltusotine/article_9b42bfe7-69a6-58be-98ff-5e2245145415.html) Today we have two guest Pharmacists to dig into the "Trust in Healthcare" theme of today's #TWIRx -- the godfather of Functional Pharmacy Robert Kress RPh., and Dr. Lauren Castle, PharmD, MS, AFMC - Founder & CEO of Functional Medicine Pharmacists Alliance. Who do you trust? What information is trustworthy and why?  Our special feature is updates on 'Cell & Gene Therapy' with McKesson's Head of Cell Gene Advanced Therapies, Joe DePinto at InspiroGene!  (https://inspirogene.com/)  Today's TWIRx is sponsored by 'Sykes & Company' the Pharmacy Accounting Jedi Masters and Independent Pharmacy Cooperative (IPC) and how they're revolutionzing digital health and new revenues with the iCare+ System!    Trust Matters, Cell and Gene, & World Pharmacists Day | TWIRx

Discover expert insights on kidney stone prevention and management in this podcast episode featuring a physician, dietitian, pharmacist, and patient. Learn about key kidney stone risk factors and explore how dietary adjustments can reduce stone recurrence. Experts discuss fluid intake strategies, medication considerations, surgical indications, and even unconventional questions about roller coasters' impact on stone passage. Tune in for actionable advice, myth-busting discussions, and interprofessional perspectives.   On today's episode we heard from: Melanie Betz, MS, RD, CSR, FNKF, FAND is a nationally recognized renal dietitian and the Founder & CEO of The Kidney Dietitian. She is a Certified Specialist in Renal Nutrition and a Fellow of both the National Kidney Foundation and the Academy of Nutrition & Dietetics. Melanie has published extensively on kidney stone prevention and nutrition, and has presented at numerous state, national, and international conferences on the topic. Through her clinical work, research, and educational outreach, she is dedicated to helping patients and professionals understand the critical role of diet in kidney health. Mark Garofoli, PharmD, MBA, BCGP, CPE, CTTS is a Clinical Associate Professor at West Virginia University School of Pharmacy and a Clinical Pain & Addiction Pharmacist. With expertise in pain management, substance use disorders, and geriatric care, he brings both clinical and personal perspectives to kidney stone discussions. Mark has shared his experience through the Pain Pod podcast, PAINWeek presentations, and a published article detailing his own kidney stone journey. Mary Raines, CRA is a retired clinical research associate with more than 30 years of experience in medical research. After learning she needed a kidney transplant, she dedicated herself to advocacy and now serves as a Patient Advocate with the National Kidney Foundation and other kidney health organizations. Mary brings both professional expertise and personal experience to her work, amplifying the voices and needs of people living with kidney disease. Andrew Rule, MD, MSc is a Professor of Medicine and Consultant Nephrologist at the Mayo Clinic in Rochester, Minnesota. He divides his time between clinical care, research, and education, with a particular focus on kidney stone disease and its link to chronic kidney disease. Dr. Rule has published extensively on the epidemiology of kidney stones and provides specialized care in the Mayo Clinic's nephrology stone clinic. Bryan Tucker, DO, MS, FASN is an Assistant Professor of Medicine in Nephrology at Baylor College of Medicine, where he serves as a clinician educator teaching medical students, residents, and fellows while caring for patients in both inpatient and outpatient settings. He holds a master's degree in nutrition from Columbia University and completed his nephrology fellowship at Yale. A Fellow of the American Society of Nephrology, Dr. Tucker has authored numerous peer-reviewed publications and book chapters and is an active contributor to The Kidney Commute podcast.   Additional Resources: Kidney Stone Information Earn CME Credit Here Do you have comments, questions, or suggestions? Email us at NKFpodcast@kidney.org. Also, make sure to rate and review us wherever you listen to podcasts.  

Taking risks with your money, career, or life goals isn't easy, especially if you don't feel secure. In this episode, Tim Ulbrich, PharmD, explores how to build both the financial and emotional foundation you need to step out of survival mode and start taking calculated risks with confidence. Episode Summary Without security, it can be difficult to take risks. In this episode, YFP Co-Founder & CEO, Tim Ulbrich, PharmD, shares how to build the financial and emotional foundation you need to move past survival mode and take bold, calculated risks You'll learn: ✅ Why having a financial “floor” is essential before taking risks ✅ How emotional security plays into financial decision-making ✅ Practical steps to create stability so you can pursue opportunities ✅ The balance between playing it safe and going after bold goals Whether it's investing, starting a new business venture, or chasing a dream, this conversation will help you create the security you need to move forward. Mentioned on the Show Watch the Your Financial Pharmacist Podcast on YouTube Learn More About Your Financial Pharmacist  

ASHP's senior education director, Cindy Von Heeringen is joined by James Hoffman, senior vice president of quality and safety, member, pharmacy and pharmaceutical sciences at St. Jude Children's Research Hospital, and Joe DiPiro, professor emeritus at Virginia Commonwealth University, School of Pharmacy, as they discuss their upcoming Midyear session that focuses on relevant trends in the external environment that will have a major impact on health-system pharmacy practice over the next five years.  The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.

Note from our guest: We are seeking your participation in a survey about pediatric vaccines BEFORE you listen to the podcast. The survey should take no longer than 5-10 minutes to complete. Survey results will be used to identify potential reasons for hesitancy when it comes to pediatric vaccines.Participation in the survey is voluntary. Participants will not encounter any costs. Pre survey: https://uofmississippi.qualtrics.com/jfe/form/SV_etgBsnrF9FJdgCaAfter listening to the podcast there is a separate survey to enter into a randomized drawing for one of ten $20 amazon gift cards. Survey expires towards the end of October 2025. Post survey: https://uofmississippi.qualtrics.com/jfe/form/SV_b7a5yDmONTpKn2KEmail the show at kids@mpbonline.orgHost: Dr. Morgan McLeod, Asst. Professor of Pediatrics and Internal Medicine at the University of Mississippi Medical Center.If you enjoyed listening to this podcast, please consider contributing to MPB: https://donate.mpbfoundation.org/mspb/podcastGuest: Ha Phan, PharmD, CDCES, BCACP (she/her/hers)Clinical Associate Professor of Pharmacy PracticePGY2 Ambulatory Care Pharmacy Residency Program Directorwebsite mentioned: The Children's Hospital of Philadelphia - vaccine ingredients Hosted on Acast. See acast.com/privacy for more information.

In this episode of the Society of Critical Care Medicine (SCCM) Podcast, host Marilyn N. Bulloch, PharmD, BCPS, FCCM, welcomes Bram Tilburgs, RN, PhD, of Radboud University Medical Center in Nijmegen, Netherlands. They discuss Dr. Tilburgs' article, “Associations Between Physical, Cognitive, and Mental Health Domains of Post-Intensive Care Syndrome and Quality of Life: A Longitudinal Multicenter Cohort Study,” published in the January 2025 issue of Critical Care Medicine. The conversation offers key insights into the prevalence and long-term effects of post-intensive care syndrome (PICS). Dr. Tilburgs' study surveyed intensive care unit (ICU) patients on their quality of life three months, twelve months, and two years after ICU discharge. The survey included physical, cognitive, and mental health domains. The findings show a significant link between PICS and diminished long-term quality of life. Drs. Bulloch and Tilburgs discuss how these results highlight the need for PICS prevention across all three domains. They review potential strategies, such as diaries to help patients better understand their ICU experience. Dr. Tilburgs also highlights the benefits of his institution's discussion group for ICU survivors. Listeners will gain key insights on the long-term effects of PICS, actionable ideas for improving ICU patient care, and ideas for future research. Resources referenced in this episode:  Associations Between Physical, Cognitive, and Mental Health Domains of Post-Intensive Care Syndrome and Quality of Life: A Longitudinal Multicenter Cohort Study (Tilburgs B, et al. Crit Care Med. 2025 Jan;53:e74-e86).

Can a decades-old drug unlock new possibilities for longevity? Rapamycin, originally discovered in the 1970s on Easter Island, was once used solely as an anti-rejection medication for organ transplants. Today, at much lower and less frequent doses, it is being studied and repurposed for its potential to extend health span, reduce inflammation, and support overall vitality. In this episode, Bryana Gregory, pharmacist and physician liaison, breaks down the history of rapamycin, the design and findings of the 2024 Pearl Study, and why proper compounding matters for bioavailability and effectiveness. She also explains how this drug works on the mTOR pathway, helping improve cellular function, brain clarity, skin health, and even bone density and lean muscle mass in some patients. If you're curious about repurposed drugs, longevity, or ways to reduce inflammation naturally, this discussion sheds light on how rapamycin may become an important tool for the future of wellness. Watch now and subscribe to our podcasts at www.HotzePodcast.com. To receive a FREE copy of Dr. Hotze's best-selling book, “Hormones, Health, and Happiness,” call 281-698-8698 and mention this podcast. Includes free shipping!

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Jonathon B. Cohen, MD, MS As the therapeutic landscape for follicular lymphoma continues to evolve, CAR T-cell therapy is emerging as a transformative option for select patients with relapsed or high-risk disease. But it also comes with a lot of important considerations, like knowing when to refer and how to manage common adverse events. Joining Dr. Charles Turck to explore how CAR T fits into the broader treatment algorithm for follicular lymphoma is Dr. Jonathan Cohen. Not only is he a Professor in the Department of Hematology and Medical Oncology at the Emory University School of Medicine, but he's also the Co-Director of the Lymphoma Program at the Winship Cancer Institute of Emory University in Atlanta.

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Jonathon B. Cohen, MD, MS As the therapeutic landscape for follicular lymphoma continues to evolve, CAR T-cell therapy is emerging as a transformative option for select patients with relapsed or high-risk disease. But it also comes with a lot of important considerations, like knowing when to refer and how to manage common adverse events. Joining Dr. Charles Turck to explore how CAR T fits into the broader treatment algorithm for follicular lymphoma is Dr. Jonathan Cohen. Not only is he a Professor in the Department of Hematology and Medical Oncology at the Emory University School of Medicine, but he's also the Co-Director of the Lymphoma Program at the Winship Cancer Institute of Emory University in Atlanta.

On this milestone episode of Unscripted, the AMCP Podcast, they celebrate the 30th anniversary of the Journal of Managed Care & Specialty Pharmacy (JMCP). Host Susan Cantrell, AMCP CEO, is joined by Laura Happe, PharmD, MPH, Editor-in-Chief of JMCP, and Pat Gleason, PharmD, BCPS, FCCP, FAMCP, Assistant Vice President, Health Outcomes at Prime Therapeutics to reflect on the journal's evolution from its 1995 launch to today's leading voice in managed care pharmacy. Highlights include JMCP's role in shaping policy, advancing research, and tackling pressing issues such as drug pricing, equity, and access—while looking ahead to the future of pharmacy innovation and collaboration. Find all of our network podcasts on your favorite podcast platforms and be sure to subscribe and like us. Learn more at www.healthcarenowradio.com/listen/

ASHP's senior education director, Cindy Von Heeringen is joined by Tyler Vest, network director of pharmacy, pharmacy supply chain at the University of Vermont Health Network, as he discusses his upcoming Midyear sessions that focus on ongoing research about the medication use process and the current state.   The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.

Join Drs. Neil Skolnik and Sara Wettergreen as they answer one of the most common questions people living with diabetes have: “What diabetes medication is best for me?”   In this episode, they'll explore how choosing the right medication depends on your individual health, lifestyle, and goals. Discover practical tips to better help you work with your care team to make informed decisions and find the best treatment plan for you.   Presented by: Neil Skolnik, MD, Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health, Abington, PA Sara Wettergreen, PharmD, BCACP, BC-ADM, Assistant Professor, Department of Clinical Pharmacy, University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences; and Ambulatory Care Clinical Pharmacist, UCHealth Lone Tree Primary Care, Aurora, CO Do you have questions or comments you'd like to share with Neil and Sara? Leave a message at (703) 755-7288. Thank you for listening, and don't forget to “follow” Diabetes Day by Day!   Diabetes Medications: Biguanides Brand: Glucophage, Fortamet, Glumetza Generic: Metformin, Metformin XR Sulfonylureas (Second Generation) Brand: Glucotrol, Amaryl, Diaβeta, Glynase Generic: Glipizide, Glipizide XL, Glimepiride, Glyburide Thiazolidinediones (TZDs) Brand: Actos, Avandia Generic: Pioglitazone, Rosiglitazone (no longer available) DPP-4 Inhibitors Brand: Januvia, Onglyza, Tradjenta, Nesina Generic: Sitagliptin, Saxagliptin, Linagliptin, Alogliptin SGLT2 Inhibitors Brand: Invokana, Farxiga, Jardiance, Steglatro, Brenzavvy Generic: Canagliflozin, Dapagliflozin, Empagliflozin, Ertugliflozin, Bexagliflozin GLP-1 Receptor Agonists Brand: Victoza, Trulicity, Ozempic, Rybelsus, Mounjaro (dual GIP/GLP-1) Generic: Liraglutide, Dulaglutide, Semaglutide, Tirzepatide Insulins (selected examples) Brand: Humalog, NovoLog, Apidra, Lantus, Basaglar, Levemir, Tresiba, Humulin N, Novolin N, Humulin R, Novolin R Generic: Insulin lispro, Insulin aspart, Insulin glulisine, Insulin glargine, Insulin detemir, Insulin degludec, NPH insulin, Regular insulin

10:05 – 10:22 (17mins) Nate Lucas for more information on Nate, go to NateLucas.com - @nlucas0 10:25 – 10:37 (17mins) Weekly Feature: “PORCELLI’S DELI!!” 10:41 – 10:56 (15mins) Salvatore Giorgianni Video games and mass shootings is there a correlation? Kids don’t play outside as much as other generations are video games creating a mental health crisisVIC SEE PRINTED ARTICLE: RFK Jr. Says Mass Shootings May Be Connected to Video Games—What Data Shows MEN’S HEALTH EXPERT: Dr. Salvatore J. Giorgianni, Jr., PharmD. is Senior Science Adviser to the Men's Health Network and a Past-Chair/Chair-Emeritus of the American Public Health Association and former Alumni Association Board Member of Columbia University School of Public Health.See omnystudio.com/listener for privacy information.

In this episode of a Mortar and Pestle, Tricia Heitman, PharmD, joins host Mike De Lisio, Vice President of North American Sales, and co-host Sebastian Denison, Clinical Compounding Pharmacist, RPh, FAARM (Candidate) to discuss leucovorin and other supplements for autism.

This episode dives into the world of glutathione with Dr. Nayan Patel, a pharmacist and wellness innovator who has spent decades researching how to make this essential antioxidant bioavailable. Dr. Patel explains why glutathione is critical for detoxification, slowing aging, boosting energy, and protecting against disease, yet has long been overlooked in medical training. The conversation covers his journey from pharmacy school to developing breakthrough delivery methods, why traditional IV and oral methods often fail, and how oxidative stress connects to nearly every chronic disease. With relatable analogies—from rusting cars to NFL offensive lines—Drs. May and Tim make the science both accessible and entertaining. Whether you're a physician, a health enthusiast, or simply curious about longevity, this rerun delivers an eye-opening look at how glutathione could change the way we age and heal.GUEST BIONayan Patel, PharmD, is a leading pharmacist, researcher, and wellness pioneer who has dedicated more than two decades to studying glutathione, the body's master antioxidant. Since 1999, he has worked alongside physicians, celebrities, CEOs, and patients worldwide, designing personalized therapies and advancing antioxidant research. Dr. Patel is the inventor of a patented topical delivery system for glutathione and the founder of Auro Wellness, where his innovations have reshaped how we approach energy, aging, and disease prevention. He is also the author of The Glutathione Revolution: Fight Disease, Slow Aging, and Increase Energy, a book that bridges science with practical strategies for optimal health.GET SOCIAL WITH US!

Andrew Maiorini, PharmD, FAHM, joined Over the Counter to discuss the importance of education and patient engagement when it comes to the pharmacist's role in addressing medication adherence.

In this episode, we cover type 1 diabetes and especially insulin delivery systems. Host Aaron Lohr talks with Grazia Aleppo, MD, from Northwestern University’s Feinberg School of Medicine and Diana Isaacs, PharmD, director of education and training in diabetes technology at the Cleveland Clinic. This episode is certified for up to 0.5 AMA PRA Category 1 credits and ABIM MOC points. However, claiming those points requires taking a pre-episode test. Then you must listen to the episode on the Endocrine Society’s Center for Learning website, followed by a post-episode test and evaluation. Please check the show notes for the appropriate link. This episode is supported by educational grants by MannKind Corp. and Insulet Corp. Show notes are available at https://www.endocrine.org/podcast/enp102 — for helpful links or to hear more podcast episodes, visit https://www.endocrine.org/podcast

ASHP's senior education director, Cindy von Heeringen is joined by Mitchell Buckley, clinical pharmacy specialist at Buckley Group Enterprises LLC, as he discusses his upcoming Midyear sessions that focus on acute care clinical pharmacy performance metrics and the unique pharmacokinetic and pharmacodynamic challenges in dosing chemotherapy, anticoagulants, and antimicrobials for obese and underweight patients.   The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.

Stephen Eckel, PharmD, MHA, FAPhA, FASHP, FCCP, is the Associate Dean for Global Engagement and an Associate Professor at the UNC Eshelman School of Pharmacy. He is the Residency Program Director for the Health System Pharmacy Administration and Leadership Residency at UNC Medical Center (he was also my RPD!). Dr. Eckel is also the co-founder of ChemoGlo and founder of Assure Medical Technologies, LLC. We talk through leadership training and his involvement in FIP and global pharmacy practice. In addition, he has a passion for entrepreneurship and we talk through how he has identified business opportunities and has created successful companies from them. It's a jam packed episode and one you don't want to miss!

It was truly an honor and a great pleasure to talk to a well-respected colleague and friend about his experience as both a pharmacist and an expert in the natural products field. He is a true embodiment of the Myth, Man and Legend. Tune in to learn more about filling in the gaps in the current healthcare climate by utilizing evidence-backed  nutraceuticals. Dr. Jeffery A. Johnson, ND, PharmD, RPh, MBA is a dedicated healthcare professional and 30-year combat veteran of the U.S. Armed Forces (USAF). A graduate of Purdue University (BS-Pharm, 1978), he later earned his Doctor of Naturopathy (2000), Doctor of Pharmacy from the University of Kansas (2003), and an MBA. Throughout his career, Dr. Johnson has spent over three decades educating and consulting with healthcare professionals and clients on the integration of nutraceuticals into personal healthcare practices—highlighting both their benefits and potential challenges. Since retiring from active military service in 2017, he has continued his mission of promoting informed, holistic healthcare practices. He currently works part-time as a self-employed Consultant Pharmacist, offering expert guidance on nutraceuticals and overall wellness strategies. Connect with Jeffery via: Email: ntrxpathconsultants@outlook.com  Linked In: Dr Jeffery A (Doc Pappy J) Johnson

Send us a textMeet Dr. Ken Thai, PharmD—CEO of 986 Degrees Corporation (a pharmacy franchise), multi-site independent pharmacy owner across Southern California and Nevada, and Adjunct Assistant Professor of Pharmacy Practice at USC and Western University. A past president of CPhA (California Pharmacists Association) and current national VP at NCPA, he was honored with the 2022 NCPA Willard B. Simmons Independent Pharmacist of the Year. His career blends leadership, education, and entrepreneurship, always anchored to better patient care.In this conversation, we trace his path from a UCLA biology degree to a USC School of Pharmacy PharmD, followed by a Community Pharmacy Practice residency at USC. We dig into how he opened and scaled multiple independents—spanning long-term care, compounding, DME, infusion, and specialty—and why he built a franchise model to mentor and multiply pharmacist-owners. You'll hear how he designs training that sticks, builds culture across locations, and keeps teams focused on outcomes.We also talk about teaching and precepting: what pharmacy students need now, the mindset shift from clinician to owner, and practical steps to evaluate a market, choose services, and launch sustainably. Dr. Thai shares playbooks on onboarding, metrics that matter, quality systems, and how associations like CPhA and NCPA shape the future of independent pharmacy and pharmacy entrepreneurship.If you're a pharmacy student, new grad, independent owner, or healthcare entrepreneur, this episode is your blueprint for growth. Drop your questions in the comments, share with a colleague who's thinking about ownership, and subscribe for more SGV stories at the intersection of leadership, small business, and patient care. Keywords: independent pharmacy, pharmacy franchise, pharmacy ownership, pharmacy management, USC School of Pharmacy, Western University of Health Sciences, CPhA, NCPA, 986 Degrees, pharmacy entrepreneur.__________Music CreditsIntroEuphoria in the San Gabriel Valley, Yone OGStingerScarlet Fire (Sting), Otis McDonald, YouTube Audio LibraryOutroEuphoria in the San Gabriel Valley, Yone OG__________________My SGV Podcast:Website: www.mysgv.netNewsletter: Beyond the MicPatreon: MySGV Podcastinfo@sgvmasterkey.com

What does long-term care pharmacy at home look like, and how is CPESN® helping lead the way? Join host John Beckner for a dynamic conversation with Leanne Haley-Brown, BS Pharm, RPh, and Patrick Chancy, PharmD, of Chancy Drugs, as they explore how LTC at home came to be and the pivotal role CPESN plays in its success.  Guests:  Leanne Haley-Brown, BS Pharm, RPh, CPESN Pharmacy Care at Home, and Patrick Chancy, PharmD, Chancy Drugs 

As more patients live beyond cancer treatment, survivorship care is becoming an essential—but often overlooked—part of the healthcare journey. This episode explores how pharmacists can support survivors through medication management, mental health awareness, lifestyle counseling, and connection to broader care resources. Tune in to learn how you can play a meaningful role in helping patients navigate life after cancer. HOSTJoshua Davis Kinsey, PharmDVP, EducationCEimpactGUESTErica Marchese, PharmD, BCPS, BCOP, BCSCP, MHAClinical Pharmacy Program DirectorCity of HopeJoshua Davis Kinsey and Erica Marchese have no relevant financial relationships to disclose.Pharmacists, REDEEM YOUR CPE HERE!CPE is available to Health Mart franchise members onlyTo learn more about Health Mart, click here: https://join.healthmart.com/CPE INFORMATION Learning ObjectivesUpon successful completion of this knowledge-based activity, participants should be able to:1. Identify common physical, emotional, and medication-related challenges faced by patients in the survivorship phase of cancer care.2. Describe the pharmacist's role in supporting survivorship through medication review, lifestyle counseling, and care coordination.0.05 CEU/0.5 HrUAN: 0107-0000-25-292-H01-PInitial release date: 9/15/2025Expiration date: 9/15/2026Additional CPE details can be found here.

As more patients live beyond cancer treatment, survivorship care is becoming an essential—but often overlooked—part of the healthcare journey. This episode explores how pharmacists can support survivors through medication management, mental health awareness, lifestyle counseling, and connection to broader care resources. Tune in to learn how you can play a meaningful role in helping patients navigate life after cancer.HOSTJoshua Davis Kinsey, PharmDVP, EducationCEimpactGUESTErica Marchese, PharmD, BCPS, BCOP, BCSCP, MHAClinical Pharmacy Program DirectorCity of HopeJoshua Davis Kinsey and Erica Marchese have no relevant financial relationships to disclose.Pharmacist Members, REDEEM YOUR CPE HERE! Not a member? Get a Pharmacist Membership & earn CE for GameChangers Podcast episodes! (30 mins/episode)CPE INFORMATIONLearning ObjectivesUpon successful completion of this knowledge-based activity, participants should be able to:1. Identify common physical, emotional, and medication-related challenges faced by patients in the survivorship phase of cancer care.2. Describe the pharmacist's role in supporting survivorship through medication review, lifestyle counseling, and care coordination.0.05 CEU/0.5 HrUAN: 0107-0000-25-292-H01-PInitial release date: 9/15/2025Expiration date: 9/15/2026Additional CPE details can be found here.Follow CEimpact on Social Media:LinkedInInstagram

Send us a textHealthcare spending continues to surge, with pharmacy costs now representing 30-40% of total healthcare spend.   In this episode of CareTalk Executive Features, David Williams speaks with Dr. Alan Pannier, SVP of Product Strategy at SmithRx, about how legacy PBMs' misaligned incentives drive up costs, the toll on patients, employers, and independent pharmacies, and how a modern PBM model focused on transparency, fair reimbursement, and aligned incentives could finally fix what's broken in pharmacy benefits.

Andrea Sikora, PharmD, MSCR, FCCM, FCCP, BCCCP, joined Over the Counter to discuss her role in drafting new guidelines that help bolster the authority of critical care pharmacists across the country.

While doctors are prescribing fewer and fewer opioids, there's one that's not going away – buprenorphine, often known by its brand name of Suboxone. Compared to other narcotics, it's harder to abuse. It's far less dangerous than the synthetic street drugs. And it reduces the risk of overdosing. But it's still an opioid that is very hard to get off of. The number of Tennesseans prescribed these opioids as addiction treatment jumped by 40% in just five years. As we look this week at all sides of a philosophy known as “harm reduction,” today we focus on access to the opioids meant to get us out of the opioid crisis.GuestsLeslie Cole, MD, addiction physician, Springfield, Tenn.Josh Draper, program manager, Sumner Prevention CoalitionTracy Frame, PharmD, professor of pharmacy practice and director of the Flourish Mobile Clinic, Belmont UniversityChap Cuthbert, community response peer support, Mental Health Cooperative

On this episode, we define anemia and describe its clinical presentations, classifications, and underlying etiologies. We evaluate current guidelines and evidence-based strategies for diagnosing and managing different types of anemia, including iron-deficiency, vitamin B12/folate-deficiency, and anemia of chronic disease.  Cole and I are happy to share that our listeners can claim ACPE-accredited continuing education for listening to this podcast episode! We have continued to partner with freeCE.com to provide listeners with the opportunity to claim 1-hour of continuing education credit for select episodes. For existing Unlimited (Gold) freeCE members, this CE option is included in your membership benefits at no additional cost! A password, which will be given at some point during this episode, is required to access the post-activity test. To earn credit for this episode, visit the following link below to go to freeCE's website: https://www.freece.com/ If you're not currently a freeCE member, we definitely suggest you explore all the benefits of their Unlimited Membership on their website and earn CE for listening to this podcast. Thanks for listening! If you want to support the podcast, check out our Patreon account. Subscribers will have access to all previous and new pharmacotherapy lectures as well as downloadable PowerPoint slides for each lecture. If you purchase an annual membership, you'll also get a free digital copy of High-Powered Medicine 3rd edition by Dr. Alex Poppen, PharmD. HPM is a book/website database of summaries for over 150 landmark clinical trials.You can visit our Patreon page at the website below:  www.patreon.com/corconsultrx We want to give a big thanks to Dr. Alex Poppen, PharmD and High-Powered Medicine for sponsoring the podcast..  You can get a copy of HPM at the links below:  Purchase a subscription or PDF copy - https://highpoweredmedicine.com/ Purchase the paperback and hardcover - Barnes and Noble website We want to say thank you to our sponsor, Pyrls. Try out their drug information app today. Visit the website below for a free trial: www.pyrls.com/corconsultrx We also want to thank our sponsor Freed AI. Freed is an AI scribe that listens, prepares your SOAP notes, and writes patient instructions. Charting is done before your patient walks out of the room. You can try 10 notes for free and after that it only costs $99/month. Visit the website below for more information: https://www.getfreed.ai/  If you have any questions for Cole or me, reach out to us via e-mail: Mike - mcorvino@corconsultrx.com Cole - cswanson@corconsultrx.com

This is a fascinating podcast episode from Dr. Lipid himself on desmosterol.  What is it?  How do we measure it?  Why should we care? Pharmacists are well-positioned to guide patients in understanding the role of desmosterol, how medications may influence its levels, the options for measuring it, and the steps to take if levels are too high or too low. Dr. Thomas Dayspring: linkedin.com/in/thomas-dayspring-md-facp-fnla-3aaa876 or @DrLipid on X  Tamara Ruggles, PharmD: linkedin.com/in/tamara-ruggles-491882251 Resource on lipids recommended by Dr. Dayspring: https://familyheart.org/ Wages PA, Kim HH, Korade Z, Porter NA. Identification and characterization of prescription drugs that change levels of 7-dehydrocholesterol and desmosterol. J Lipid Res. 2018 Oct;59(10):1916-1926. doi: 10.1194/jlr.M086991. Epub 2018 Aug 7. PMID: 30087204; PMCID: PMC6168312.  Available at:  https://pubmed.ncbi.nlm.nih.gov/30087204/  The Geriatric Pharmacy Focus podcast is for general informational purposes only and does not constitute the practice of medicine, nursing or other professional health care services, including the giving of medical advice, and no doctor/patient relationship is formed. The use of information on this podcast or materials linked from this podcast is at the user's own risk. The content of this podcast is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Users should not disregard or delay in obtaining medical advice for any medical condition they may have and should seek the assistance of their health care professionals for any such conditions.

Jasmine Gonzalvo, PharmD, MPH, CDCES, FADCES, and Honey Yang Estrada, MPH, CHW, join this episode to discuss the vital role of community health workers (CHWs) in diabetes care. They share strategies for recruiting CHWs, integrating them into interprofessional care teams, and leveraging their lived experience to build trust and address barriers beyond the clinic walls. The conversation emphasizes listening to CHWs, fostering sustainable partnerships, and shifting power to communities—not just checking a box—to reduce disparities and drive better outcomes. Listen to more episodes of The Huddle at adces.org/perspectives/the-huddle-podcast.Learn more about ADCES and the many benefits of membership at adces.org/join.

“All of these TKIs [tyrosine kinase inhibitors] inhibit BCR-ABL1 in some way, shape, or form. When BCR-ABL1 is mutated, it has uncontrolled tyrosine kinase activity, leading to rapid cell proliferation. When we then inhibit that BCR-ABL1 that's been mutated, we disrupt this abnormal signaling pathway that drives CML [chronic myeloid leukemia] cell proliferation and survival, ultimately leading to decreased cancer cell growth, increased apoptosis or cell death, and potentially inducing a disease remission,” Samantha Maples, PharmD, BCOP, clinical pharmacy specialist supervisor for hematology and cellular therapy at Allegheny Health Network in Pittsburgh, PA, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about the BCR-ABL1 inhibitor drug class.   Music Credit: “Fireflies and Stardust” by Kevin MacLeod  Licensed under Creative Commons by Attribution 3.0   Earn 0.5 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by September 5, 2026. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.  Learning outcome: Learner will report an increase in knowledge related to the use of BCR-ABL1 inhibitors in the treatment of CML. Episode Notes   Complete this evaluation for free NCPD.  ONS Podcast™ episodes: Pharmacology 101 series Episode 322: Nursing Strategies to Reduce Readmission Rates for Patients With Cancer Episode 215: Navigate Updates in Oral Adherence to Cancer Therapies ONS Voice articles: Adherence to Oral Anticancer Medication Combination Therapy Shows Promise for Chronic Myeloid Leukemia The Case of the Medication Modification The Case of the Safety Session ONS course: Safe Handling Basics Clinical Journal of Oncology Nursing articles: Targeted Drug Therapies: Beyond Blood Counts and Chemistries Oncology Nursing Forum articles: Adherence and Coping Strategies in Outpatients With Chronic Myeloid Leukemia Receiving Oral Tyrosine Kinase Inhibitors Fear of Progression in Outpatients With Chronic Myeloid Leukemia on Oral Tyrosine Kinase Inhibitors Other ONS resources: Biomarker Database Financial Toxicity Huddle Card Tyrosine Kinase Inhibitors Huddle Card Oral Anticancer Medication Care Compass: Resources for Interprofessional Navigation Oral Anticancer Medication Learning Library National Comprehensive Cancer Network National Comprehensive Cancer Network patient resources To discuss the information in this episode with other oncology nurses, visit the ONS Communities.   To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library.  To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode  “The IRIS study led to the approval of the BCR-ABL1 and TKI, imatinib, for CML in 2001 and completely changed the landscape of CML treatment. Then came the second-generation BCR-ABL1 TKIs: dasatinib in 2006, quickly followed by nilotinib in 2007. Thereafter came our second-generation, bosutinib, and our first approved third-generation TKI, ponatinib, both in 2012, which was a huge milestone as ponatinib overcomes resistance to the T315 I mutation, which no previously approved TKIs worked against.” TS 2:16 “The newest approved TKI, asciminib, is an allosteric inhibitor that binds to a different pocket on the BCR-ABL kinase via allosteric binding to the ABL myristoyl pocket. It's what's called a STAMP inhibitor, where STAMP stands for ‘specifically targeting the ABL myristoyl pocket.' And while all the TKIs target the BCR-ABL1 binding site, they can also inhibit different off-target kinases. And these differences in off-target inhibition are responsible for some of the different toxicities we see among the TKIs.” TS 4:51 “As a class, common toxicities include nausea; vomiting; diarrhea; cardiac toxicities, including cardiac arrhythmias and congestive heart failure; metabolic abnormalities such as hypercholesterolemia and hypertriglyceridemia; nephrotoxicity; hepatic toxicity; hemorrhaging and bleeding; as well as cytopenia. Individually, some of these agents are more likely to cause certain side effects compared to others, and there are unique toxicities associated with certain TKIs.” TS 8:10 “We've moved to using preemptive loperamide [in our clinic] for the first three days of starting treatment, because it's really hard to get patients to continue to take a medication if they have such severe diarrhea that they end up in the hospital or they're unable to leave their house. A lot of times, we will proactively give patients antiemetics and loperamide to help with the nausea, vomiting, and diarrhea. And then we can back off to an as-needed basis once they've been established on treatment. We can also use medications to help manage long-term complications that can require supportive care, such as statin therapy for high cholesterol, levothyroxine for hypothyroidism, anticoagulants for any venous thromboembolism, and antihypertensive medications for managing any new or worsening high blood pressure.” TS 12:44 “We are continually seeing these agents expand their indications to different lines of therapy, as well as more TKIs being approved for acute lymphoblastic leukemia. For example, asciminib just got approved in the frontline setting within the last year, whereas previously it was only approved in relapsed refractory setting. Last year, imatinib was the first BCR-ABL1 TKI to come out with a commercially supplied suspension option as well, which is huge in the pediatric space and [for] our adult patients who are unable to swallow tablets for other clinical reasons.” TS 21:22 “There is more information being published on the safe discontinuation of these medications with treatment-free remissions, and more information is coming out about who would be eligible and who can have the option to stop these treatments instead of having a lifelong chronic condition requiring continuous treatment. We're seeing more patients in clinical practice be able to stop BCR-ABL1 treatment, which has been a great development in CML.” TS 25:29

Tim Ulbrich and Tim Baker tackle one of the most common questions we hear from pharmacists: “Do I need this whole life insurance policy?” They dive into who needs coverage, common misconceptions, and why the “buy term and invest the difference” strategy may be the smarter approach. Episode Summary YFP Co-Founder & CEO, Tim Ulbrich, PharmD, and YFP Co-Founder & COO, Tim Baker, CFP®, RLP®, RICP®, tackle one of the most common questions we hear from pharmacists: “Do I need this whole  life insurance policy?” We've seen an increasing number of pharmacists with expensive whole life insurance policies that are often complex, costly, and not always the best fit. In this video, Tim and Tim break down: ✅ Who actually needs life insurance (and who doesn't) ✅ The role life insurance should play in your financial plan ✅ The key differences between term life and whole life coverage ✅ Why “buy term and invest the difference” can often be the smarter strategy ✅ The conflicts of interest that sometimes drive whole life sales By the end, you'll better understand the benefits, costs, and misconceptions around whole life insurance so you can make an informed decision about what's right for your financial future. Mentioned on the Show Join APhA - Get 25% Off with Code YFP Life Insurance for Pharmacists: The Ultimate Guide Your Financial Pharmacist Your Financial Pharmacist on YouTube

Effective management of adverse events and addressing barriers to care are critical to optimizing outcomes and maintaining quality of life for patients receiving CDK4/6 inhibitors. In this episode, CANCER BUZZ speaks with Julia Lea Ziegengeist, PharmD, BCOP, clinical pharmacist coordinator in solid tumor oncology at Atrium Health Levine Cancer Institute about proactive, team-based strategies to identify, monitor, and manage treatment-related toxicities in patients with early-stage and metastatic HR-positive, HER2-negative breast cancer. Dr. Ziegengeist sheds light on the patient journey, the roles of various multidisciplinary care team members, and useful resources for language and literacy barriers. “I think the biggest thing that is specific to CDK4/6 inhibitors is... eligibility criteria and when we're using the drugs in what setting, having those monitoring protocols and getting that multidisciplinary collaboration is really key.” – Julia Lea Ziegengeist, PharmD, BCOP   Julia Lea Ziegengeist, PharmD, BCOP   Clinical Pharmacist Coordinator, Solid Tumor Oncology   Levine Cancer Institute   Atrium Health   Charlotte, NC       Resources: ACCC Resource: CDK4/6 Inhibitors Management  ACCC CDK4/6 Inhibitors Infographic 

Follow Jason on Tik Tok @CarnivRX   If you liked this and want to learn more go to my new website www.DrAnthonyChaffee.com

On this episode, we define obsessive-compulsive disorder (OCD) and describe its clinical presentations, diagnostic criteria, and underlying pathophysiology. We evaluate current guidelines and evidence-based treatment strategies for managing OCD, including pharmacologic and non-pharmacologic interventions. We also, compare and contrast the efficacy, safety profiles, and appropriate use of selective serotonin reuptake inhibitors (SSRIs), cognitive behavioral therapy (CBT), and other emerging treatment modalities for OCD.  Dr. David Osser's psychopharmacology Algorithm Website  Cole and I are happy to share that our listeners can claim ACPE-accredited continuing education for listening to this podcast episode! We have continued to partner with freeCE.com to provide listeners with the opportunity to claim 1-hour of continuing education credit for select episodes. For existing Unlimited (Gold) freeCE members, this CE option is included in your membership benefits at no additional cost! A password, which will be given at some point during this episode, is required to access the post-activity test. To earn credit for this episode, visit the following link below to go to freeCE's website: https://www.freece.com/ If you're not currently a freeCE member, we definitely suggest you explore all the benefits of their Unlimited Membership on their website and earn CE for listening to this podcast. Thanks for listening! If you want to support the podcast, check out our Patreon account. Subscribers will have access to all previous and new pharmacotherapy lectures as well as downloadable PowerPoint slides for each lecture. If you purchase an annual membership, you'll also get a free digital copy of High-Powered Medicine 3rd edition by Dr. Alex Poppen, PharmD. HPM is a book/website database of summaries for over 150 landmark clinical trials.You can visit our Patreon page at the website below:  www.patreon.com/corconsultrx We want to give a big thanks to Dr. Alex Poppen, PharmD and High-Powered Medicine for sponsoring the podcast..  You can get a copy of HPM at the links below:  Purchase a subscription or PDF copy - https://highpoweredmedicine.com/ Purchase the paperback and hardcover - Barnes and Noble website We want to say thank you to our sponsor, Pyrls. Try out their drug information app today. Visit the website below for a free trial: www.pyrls.com/corconsultrx We also want to thank our sponsor Freed AI. Freed is an AI scribe that listens, prepares your SOAP notes, and writes patient instructions. Charting is done before your patient walks out of the room. You can try 10 notes for free and after that it only costs $99/month. Visit the website below for more information: https://www.getfreed.ai/  If you have any questions for Cole or me, reach out to us via e-mail: Mike - mcorvino@corconsultrx.com Cole - cswanson@corconsultrx.com